CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel Sells $50,398.92 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

CRISPR Therapeutics Stock Up 2.0 %

Shares of CRSP stock opened at $49.00 on Thursday. The stock has a market cap of $4.16 billion, a price-to-earnings ratio of -18.01 and a beta of 1.68. The business’s fifty day moving average is $47.14 and its 200 day moving average is $53.59. CRISPR Therapeutics AG has a twelve month low of $37.55 and a twelve month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $12.31 million. The firm’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.98) earnings per share. Equities research analysts expect that CRISPR Therapeutics AG will post -5.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CRSP. Barclays lowered their price objective on CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 6th. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Guggenheim reiterated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday, June 28th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Friday, August 16th. Finally, Truist Financial lowered their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and an average target price of $75.19.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds have recently added to or reduced their stakes in CRSP. Global Trust Asset Management LLC boosted its holdings in CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC boosted its holdings in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC lifted its holdings in shares of CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock valued at $33,000 after purchasing an additional 307 shares in the last quarter. Riggs Asset Managment Co. Inc. lifted its holdings in shares of CRISPR Therapeutics by 66.7% during the first quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock valued at $34,000 after purchasing an additional 200 shares in the last quarter. Finally, Itau Unibanco Holding S.A. bought a new position in shares of CRISPR Therapeutics during the second quarter valued at $35,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.